European Union - English - EMA (European Medicines Agency)

astrazeneca ab - budesonide, formoterol fumarate dihydrate, glycopyrronium bromide - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, - riltrava aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2 agonist or combination of a long-acting beta2 agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.1).

Canada - English - Health Canada

astrazeneca canada inc - budesonide; glycopyrronium (glycopyrronium bromide); formoterol fumarate dihydrate - aerosol, metered dose - 160mcg; 7.2mcg; 5mcg - budesonide 160mcg; glycopyrronium (glycopyrronium bromide) 7.2mcg; formoterol fumarate dihydrate 5mcg - antimuscarinics antispasmodics

Singapore - English - HSA (Health Sciences Authority)

astrazeneca singapore pte ltd - budesonide; formoterol fumarate dihydrate; glycopyrronium bromide eqv glycopyrronium - aerosol, metered - budesonide 160 μg/actuation; formoterol fumarate dihydrate 5.0 μg/actuation; glycopyrronium bromide eqv glycopyrronium 7.2 μg/actuation

European Union - English - EMA (European Medicines Agency)

astrazeneca ab - formoterol fumarate dihydrate, glycopyrronium bromide, budesonide - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, - trixeo aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long acting beta2 agonist or combination of a long-acting beta2 agonist and a long acting muscarinic antagonist.

Israel - English - Ministry of Health

astrazeneca (israel) ltd - budesonide; formoterol fumarate dihydrate; glycopyrronium - suspension for inhalation - formoterol fumarate dihydrate 5 mcg; glycopyrronium 7.2 mcg; budesonide 160 mcg - budesonide - trixeo aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist